Medicenna Therapeutics to Participate in Two Healthcare Investor Conferences in February 2025
Rhea-AI Summary
Medicenna Therapeutics Corp. (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company, has announced its participation in two major healthcare investor conferences in February 2025. The company will present at the Oppenheimer Annual Healthcare Life Sciences Conference on Tuesday, February 11, 2025, at 9:20 a.m. ET, with a webcast available for 180 days following the event.
Additionally, Medicenna will participate in a fireside chat at the B. Riley Securities Precision Oncology & Radiopharma Conference on Friday, February 28, 2025, in New York City. The company's management team will be available for one-on-one meetings with investors during both conferences. Interested investors can schedule meetings through conference representatives or by contacting Medicenna's investor relations team directly.
Positive
- None.
Negative
- None.
TORONTO and HOUSTON, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines for the treatment of cancer, and inflammatory and autoimmune diseases, today announced that its management team will participate in two upcoming investor conferences in February 2025. The company will also host one-on-one meetings with investors during these events.
Oppenheimer Annual Healthcare Life Sciences Conference 2025
Format: Presentation
Date: Tuesday, February 11, 2025, at 9:20 a.m. ET
Webcast link: https://wsw.com/webcast/oppenheimer39/mdna/2754560
Webcast and replay information for this event will be available on the investor relations section of Medicenna’s website on the Events & Presentations page. The webcast replay will be available for 180 days following the event.
B. Riley Securities Precision Oncology & Radiopharma Conference 2025
Format: Fireside Chat
Date: Friday, February 28, 2025
Location: New York City, NY
One-on-One Investor Meetings
In addition to the presentations, Medicenna’s management team will be available for one-on-one meetings with investors at both conferences. Investors interested in scheduling a meeting can contact their respective conference representatives or reach out to Medicenna’s investor relations team at ir@medicenna.com.
About Medicenna Therapeutics
Medicenna is a clinical-stage immunotherapy company focused on developing novel, highly selective versions of IL-2, IL-4 and IL-13 Superkines and first-in-class Empowered Superkines. Medicenna’s long-acting IL-2 Superkine, MDNA11, is a next-generation IL-2 with superior affinity toward CD122 (IL-2 receptor beta) and no CD25 (IL-2 receptor alpha) binding, thereby preferentially stimulating cancer-killing effector T cells and NK cells. MDNA11 is being evaluated in the Phase 1/2 ABILITY-1 Study (NCT05086692) as a monotherapy and in combination with pembrolizumab. Medicenna’s IL-4 Empowered Superkine, bizaxofusp (formerly MDNA55), has been studied in 5 clinical trials enrolling over 130 patients, including a Phase 2b trial for recurrent GBM, the most common and uniformly fatal form of brain cancer. Bizaxofusp has obtained FastTrack and Orphan Drug status from the FDA and FDA/EMA, respectively. Medicenna’s early-stage high-affinity IL-2β biased IL-2/IL-15 Super-antagonists, from its MDNA209 platform, are being evaluated as potential therapies for autoimmune and graft-versus host diseases. Medicenna’s early-stage BiSKITs™ (Bifunctional SuperKine ImmunoTherapies) and the T-MASK™ (Targeted Metalloprotease Activated SuperKine) programs are designed to enhance the ability of Superkines to treat immunologically “cold” tumors.
For more information, please visit www.medicenna.com, and follow us on Twitter and LinkedIn.
Forward-Looking Statements
This news release contains forward-looking statements within the meaning of applicable securities laws. Forward-looking statements include, but are not limited to, express or implied statements regarding the future operations of the Company, estimates, plans, strategic ambitions, partnership activities and opportunities, objectives, expectations, opinions, forecasts, projections, guidance, outlook or other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expect”, “believe”, “seek”, “potentially” and similar expressions. and are subject to risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include the risks detailed in the latest annual information form of the Company and in other filings made by the Company with the applicable securities regulators from time to time in Canada.
The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date hereof and except as required by law, we do not intend and do not assume any obligation to update or revise publicly any of the included forward-looking statements.
This news release contains hyperlinks to information that is not deemed to be incorporated by reference in this new release.
Investor Contact:
Christina Cameron
Investor Relations
ir@medicenna.com
(647) 953-0673
FAQ
When is Medicenna Therapeutics (MDNAF) presenting at the Oppenheimer Healthcare Conference 2025?
How long will the MDNAF Oppenheimer Conference webcast be available for replay?
Where can investors access the webcast for MDNAF's Oppenheimer Conference presentation?
When and where is MDNAF participating in the B. Riley Securities Conference 2025?
How can investors schedule one-on-one meetings with MDNAF management at these conferences?
